| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +674K | 100% | $3.71 | +$2.5M |
| Sells | 0 | ||||
| Net | +3 | +674K | 100% | +$2.5M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | Director | $13.4M | +$2.3M | +20.8% | Oct 30, 2024 |
| Steven Salamon | Director | $10.2M | +$100K | +0.99% | Oct 30, 2024 |
| Aharon Gil | Director | $9.97M | +$100K | +1.01% | Oct 30, 2024 |
| Gerard Michel | CHIEF EXECUTIVE OFFICER, Director | $1.92M | Oct 22, 2024 | ||
| Vojo Vukovic | Chief Medical Officer | $472K | Mar 19, 2024 | ||
| David L. Hoffman | Gen'l Counsel, Cco & Secy | $277K | Mar 19, 2024 | ||
| Sandra Pennell | Svp Of Finance, Pfo And Pao | $227K | Mar 19, 2024 | ||
| John Purpura | Chief Operating Officer | $125K | Feb 8, 2023 | ||
| Kevin Muir | Gm Interventional Oncology | $69.1K | Mar 19, 2024 | ||
| John Richard Sylvester | Director | $31.7K | May 23, 2024 | ||
| Anthony Dias | Vp Finance | Feb 8, 2023 | |||
| Bridget Martell | Director | May 23, 2024 | |||
| Roger G. Stoll Phd | Director | May 23, 2024 | |||
| Christine Padula | Interim Principal Accounting Officer | Sep 1, 2021 | |||
| Johnny John | Svp Clinical Dev & Med Affairs | Feb 8, 2023 | |||
| Elizabeth Czerepak | Director | May 23, 2024 | |||
| Martha S. Rook | Chief Operating Officer | Mar 18, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|